Healthcare · NSE: AUROPHARMA · BSE: 524804
Aurobindo Pharma: how the business works
Aurobindo Pharma makes generic medicines and drug ingredients, mostly sold in the US and Europe, and earned ₹33,653 crore of revenue in FY26.
Follow Aurobindo Pharma
Email me when Aurobindo Pharma's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Aurobindo Pharma Limited · Hyderabad, Telangana · Founded 1986
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹33,653 cr
- Profit to shareholders, FY26
- ₹3,505 cr
- Manufacturing plants, FY26
- 33
- Permanent employees, 31 Mar 2026
- 27,000+
- Promoter holding, 30 Sep 2026
- 51.88%
The short version
Aurobindo Pharma in 5 points
1 · What it sells
Aurobindo Pharma makes generic medicines and drug ingredients (APIs), mostly for the US and Europe, and its FY26 revenue from operations was ₹33,653 crore.
2 · Who pays it
In FY26, customers in the US paid 42.7% of Aurobindo's revenue, Europe 31.8%, other countries 15.7% and India 9.9%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Aurobindo kept ₹10.3 as profit after ₹0.2 of one-off charges; its EBITDA, which leaves out other income, was 20.2% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Aurobindo reports a single segment, so it does not say which business earns its FY26 EBITDA of ₹6,782 crore (Cityfort calculation); US formulations were its largest business, with ₹14,408 crore of FY26 sales.
5 · The one thing to watch
Eugia Unit-I, about 2% of group revenue, received a US FDA warning letter on 14 Aug 2026, and the FDA classified Eugia Unit-III and Lannett's Seymour plant as OAI in 2026.
Sources: From Aurobindo Pharma's FY26 annual report, its Q4 FY26 and Q2 FY27 press releases, and its 2026 exchange filings · checked
01Where the money goes · FY26
Where does ₹100 of Aurobindo Pharma's money go?
Aurobindo Pharma · FY26
Receipt for every ₹100
| Materials and goods bought | ₹39.5 |
|---|---|
| Employees | ₹15.2 |
| Other running costs | ₹23.8 |
| Depreciation and amortisation | ₹5.2 |
| Interest | ₹1.1 |
| One-off charge | ₹0.2 |
| Tax, less small joint-venture and minority items | ₹4.7 |
| Kept as profit for shareholders | ₹10.3 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Of every ₹100 that came in (revenue ₹33,653 crore + other income ₹492 crore), from the money flow above; each line ÷ ₹34,145 crore × 100 (Cityfort calculation).
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Aurobindo Pharma do?
Buyers in the US, Europe and other countries pay Aurobindo for generic medicines and drug ingredients. Most of the money goes on materials, staff and running costs. In FY26, ₹10.3 of every ₹100 that came in was left as profit.
- In FY26 customers in the US paid 42.7% of Aurobindo's revenue, Europe 31.8%, other countries 15.7% and India 9.9%.
- Of every ₹100 that came in during FY26, ₹39.5 went on materials and goods bought, ₹15.2 on staff and ₹23.8 on other running costs.
03Who pays it
Who pays Aurobindo Pharma?
Customers in the US
42.7%
of revenue
Generic tablets, capsules and injectables. The FY26 sustainability report lists generic customers, major pharma companies, institutions and health care professionals as customer types.
Customers in Europe
31.8%
of revenue
Generic medicines sold in European countries. Europe's share rose from 29.1% in FY25 to 31.8% in FY26 (Cityfort calculation).
Customers in other countries
15.7%
of revenue
Medicines, HIV medicines and APIs sold outside the US, Europe and India.
Customers in India
9.9%
of revenue
Includes APIs sold to Indian drug makers as well as branded medicines.
- Customers in the US42.7%
- Customers in Europe31.8%
- Customers in other countries15.7%
- Customers in India9.9%
How spread out the customers are
No single customer paid Aurobindo 10% or more of its revenue in FY26 or FY25, according to the segment note. Shares are of FY26 revenue by customer location (Cityfort calculation from the annual report's figures).
04How it makes money
How does Aurobindo Pharma make money?
Many low-priced generics, made at scale in its own plants; launches and approved plants drive profit.
Aurobindo sells hundreds of generic medicines, each priced low. Materials and goods bought took ₹40.1 per ₹100 of FY26 revenue (Cityfort calculation). Profit depends on new launches, such as 42 in the US in FY26, replacing sales that fade.
EBITDA per ₹100 of revenue (Cityfort calculation)
₹18.0₹20.2
FY22 to FY26
- Scientists develop generic versions: R&D was ₹1,590 crore in FY26.
- Aurobindo files for approval: 900 US applications filed and 747 approved by 30 Sep 2026.
- 33 plants make ingredients and medicines; US sales need plants that pass US FDA inspections.
- Customers in the US and Europe buy most of them: 74.4% of FY26 revenue.
- Single products can fade: management said lower generic Revlimid sales held back FY26 US growth.
- Cash from operations (₹5,526 crore in FY26) pays for plants and purchases such as Lannett.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Aurobindo Pharma?
US formulations
42.8%Generic medicines sold in the US. Business-line figures from the press releases; Aurobindo reports one audited segment. FY23–FY25 add the separate Puerto Rico row (Cityfort calculation), as FY22 already did.
Revenue ₹14,408 cr
Europe formulations
30.7%Generic medicines sold across Europe.
Revenue ₹10,315 cr
Growth markets
10.4%Other countries, including India's branded medicines. FY22 is as first reported, before a later move of some sales between growth markets and ARV.
Revenue ₹3,499 cr
ARV
4.1%HIV medicines.
Revenue ₹1,384 cr
APIs
12%Active ingredients sold to other drug makers.
Revenue ₹4,047 cr
How the mix changed
- US formulations
- Europe formulations
- Growth markets
- ARV
- APIs
Revenue by segment, FY22 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Aurobindo Pharma done?
Revenue
₹33,653 crFY26
Revenue rose every year, from ₹23,455 crore in FY22 to ₹33,653 crore in FY26. Q2 FY27 revenue was ₹10,263 crore, with Lannett included from 29 Jun 2026.
₹ crore
See the numbers
Net profit
₹3,505 crFY26
Profit to shareholders fell to ₹1,928 crore in FY23, then rose to ₹3,505 crore in FY26. Q2 FY27 profit was ₹1,126 crore, against ₹848 crore a year earlier.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹10.4FY26
EBITDA per ₹100 of revenue (Cityfort calculation on reported profit before tax) fell from ₹18.0 in FY22 to ₹14.9 in FY23, then reached ₹20.2 in FY26, against the company's own 20.4%.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹2,422 crFY26
Free cash flow was negative in FY23 and FY24, then ₹2,422 crore in FY26, from ₹5,526 crore of operating cash after ₹3,105 crore of capital spending.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (8)
07Who runs it
Who runs Aurobindo Pharma, and did they deliver?
K. Nithyananda Reddy
Vice Chairman and Managing Director
Promoter group; held 4.37% of the shares on 30 Sep 2026.
Dr M. Madan Mohan Reddy
Whole-time Director
P. V. Ramprasad Reddy
Non-executive Director
Promoter; held 3.07% of the shares on 30 Sep 2026.
Dr Satakarni Makkapati
Non-executive Director
Also CEO of the biosimilars, vaccines and peptides business.
Santhanam Subramanian
Chief Financial Officer
B. Adi Reddy
Company Secretary
What they said, and what happened
1 partly delivered · 2 too early to tell
Said on 10 Feb 2026
Management said on the Q3 FY26 call that its internal FY26 EBITDA margin target was "mostly on the higher side of 20% to 21%".
Partly deliveredWhat happened
The company's own FY26 EBITDA margin was about 20.4%: inside the range, but not at its higher side.
Said on 22 May 2026
Management said on the Q4 FY26 call that it expected FY27 EBITDA margins to sustain and progressively improve to above 21%.
Too early to tellWhat happened
The company's own EBITDA margin was 20.8% in H1 FY27 (Cityfort calculation from its quarterly figures), or 21.0% before a one-time ₹43 crore lease item in Q1 FY27.
Said on 6 Aug 2026
Management said on 6 Aug 2026 that FY27 would bring double-digit revenue growth and EBITDA above ₹8,000 crore, on its own measure.
Too early to tellWhat happened
H1 FY27 revenue was ₹19,413 crore, 20.2% more than in H1 FY26, and the company's own EBITDA was ₹4,037 crore (Cityfort calculations).
Sources (7)
- Integrated Annual Report 2025-26 (FY26)
- Shareholding pattern as of 30 Sep 2026 (Reg. 31)
- Q3 FY26 earnings call transcript (call of 10 Feb 2026)
- Q4 FY26 earnings call transcript (call of 22 May 2026)
- Earnings presentation, Q2 FY27
- Earnings presentation, Q1 FY27
- Q1 FY27 earnings call transcript (call of 6 Aug 2026)
08What could go wrong
What could go wrong for Aurobindo Pharma?
- Regulation
US FDA plant actions
Eugia Unit-I received a US FDA warning letter on 14 Aug 2026; the company said it gives about 2% of group revenue. Eugia Unit-III and Lannett's Seymour plant were classified OAI in 2026.
Watch Re-inspections, and any new warning letter or import restriction at these three plants.
- Pricing
Reliance on US generics
US formulations were 42.8% of FY26 revenue. US sales fell from ₹14,816 crore in FY25 to ₹14,408 crore in FY26; management said lower generic Revlimid sales held growth back.
Watch US formulation sales each quarter: ₹4,555 crore in Q2 FY27, including Lannett.
- Governance
Promoter pledge
Promoters had pledged 11.99% of their shares on 30 Sep 2026, down from 23.65% on 31 Mar 2026. Lenders can sell pledged shares if the loans are not repaid.
Watch The pledged share count in each quarterly shareholding filing.
- Execution
Lannett integration
Aurobindo paid an enterprise value of US$250 million for Lannett, completed on 29 Jun 2026. Its sales are not shown separately, and its Seymour plant was classified OAI on 11 Nov 2026.
Watch Whether the company reports Lannett's sales, and the Seymour plant's status.
- Currency
Currency swings
International sales were 92% of Q2 FY27 revenue. Europe sales rose 27.5% in rupees but 18% in euros in Q2 FY27, so currency moves changed the reported growth.
Watch Growth in US dollars and euros beside rupee growth in each press release.
- Execution
Large new projects
Capital spending was ₹3,105 crore in FY26. The TheraNym biologics plants for MSD include a second unit that the company's Q2 FY27 presentation (4 Nov 2026) puts at about US$180 million, ready for qualification in 2030.
Watch TheraNym Unit 1 qualification, which the company said on 4 Nov 2026 it expects by Mar 2027.
Sources (12)
- Eugia Unit-I receives US FDA warning letter
- Eugia Unit-III (Pashamylaram) US FDA inspection classified OAI
- Lannett (Seymour, IN) US FDA inspection classified OAI
- Press release, Q4 FY26 and FY26 results
- Q4 FY26 earnings call transcript (call of 22 May 2026)
- Press release, Q2 FY27 results
- Shareholding pattern as of 30 Sep 2026 (Reg. 31)
- Shareholding pattern as of 31 Mar 2026 (Reg. 31)
- Reg. 30 disclosure: agreement to acquire Lannett Company (EV US$250 million)
- Completion of Lannett acquisition (effective 29 Jun 2026)
- Integrated Annual Report 2025-26 (FY26)
- Earnings presentation, Q2 FY27
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year from FY22 to FY26, to ₹33,653 crore, and H1 FY27 revenue was 20.2% higher than in H1 FY26.
- Europe formulation sales rose from ₹6,480 crore in FY22 to ₹10,315 crore in FY26.
- On 31 Mar 2026 cash and liquid investments were ₹2,941 crore more than borrowings (Cityfort calculation).
- Free cash flow was ₹2,422 crore in FY26, after negative years in FY23 and FY24.
- India Ratings affirmed its IND AA+/Stable rating on 11 Mar 2025.
What critics point to
- The US FDA issued a warning letter for Eugia Unit-I and classified two other plants as OAI in 2026.
- Promoters had pledged 11.99% of their shares on 30 Sep 2026.
- US formulation sales fell from ₹14,816 crore in FY25 to ₹14,408 crore in FY26.
- Profit to shareholders rose 0.5% in FY26, to ₹3,505 crore.
- Q2 FY27's US growth includes Lannett, whose sales are not shown separately.
10What to watch next
What should you watch next at Aurobindo Pharma?
Next event
Q3 FY27 results
Date not announced yet.
Plant inspections
Progress on the Eugia Unit-I warning letter (14 Aug 2026) and the OAI status of Eugia Unit-III and Lannett's Seymour plant.
FY27 guidance
Management said on 5 Nov 2026 it expects double-digit FY27 revenue growth and EBITDA above ₹8,000 crore; H1 FY27 EBITDA was ₹4,037 crore on its own measure.
Promoter pledge
Promoters had pledged 11.99% of their shares on 30 Sep 2026; the Dec 2026 shareholding filing shows the next figure.
11Key facts
Key facts about Aurobindo Pharma
- What does Aurobindo Pharma do?
- Aurobindo Pharma, based in Hyderabad, makes generic medicines (copies of medicines whose patents have ended) and the active ingredients that go into them. In FY26 its US medicine sales were ₹14,408 crore and its Europe sales ₹10,315 crore.
- How does Aurobindo Pharma make money?
- Aurobindo Pharma earns most of its money selling finished medicines (formulations): ₹29,606 crore, 88.0% of FY26 revenue. Sales of drug ingredients (APIs) to other drug makers brought in ₹4,047 crore, 12.0%.
- Who pays Aurobindo Pharma?
- In FY26 customers in the US paid 42.7% of Aurobindo Pharma's ₹33,653 crore revenue, Europe 31.8%, other countries 15.7% and India 9.9%. No single customer paid 10% or more of its FY26 revenue.
- How big is Aurobindo Pharma?
- Aurobindo Pharma reported FY26 revenue of ₹33,653 crore and profit to shareholders of ₹3,505 crore. Its FY26 sustainability report lists 28 plants in India and 5 abroad, and more than 27,000 permanent employees on 31 Mar 2026.
- Who owns Aurobindo Pharma?
- On 30 Sep 2026 the promoter group owned 51.88% of Aurobindo Pharma, Indian institutions 24.42%, foreign investors 17.41% and others 6.29%. Aurobindo Pharma's promoters had pledged 11.99% of their shares, equal to 6.22% of all shares.
- How much debt does Aurobindo Pharma have?
- On 31 Mar 2026 Aurobindo Pharma had borrowings of ₹7,676 crore and cash and liquid investments of ₹10,618 crore, so it held ₹2,941 crore more cash than debt (Cityfort calculation).
- How did Aurobindo Pharma do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Aurobindo Pharma's revenue rose 23.9% from a year earlier to ₹10,263 crore, and profit to shareholders was ₹1,126 crore against ₹848 crore. The quarter includes Lannett, bought on 29 Jun 2026.
- What has Aurobindo Pharma bought recently?
- Aurobindo Pharma completed its purchase of US generics maker Lannett on 29 Jun 2026, at an enterprise value of US$250 million. It also bought a Khandelwal Laboratories business in India (₹325 crore, agreed Jan 2026) and 80% of A1 Biochem's contract research business (Oct 2026).
Sources (10)
- Integrated Annual Report 2025-26 (FY26)
- Press release, Q4 FY26 and FY26 results
- Shareholding pattern as of 30 Sep 2026 (Reg. 31)
- Press release, Q2 FY27 results
- Earnings presentation, Q2 FY27
- Completion of Lannett acquisition (effective 29 Jun 2026)
- Reg. 30 disclosure: agreement to acquire Lannett Company (EV US$250 million)
- Reg. 30 disclosure: business transfer of Khandelwal Laboratories non-oncology formulations business
- Reg. 30 disclosure: Apitoria to acquire 80% of A1 Biochem contract research business (EV US$17 million)
- Completion of A1 Biochem acquisition
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Aurobindo Pharma sell?
US formulations
Finished generic medicines sold in the US, including injectables made by its subsidiary Eugia. ₹14,408 crore in FY26, 42.8% of revenue. Since 29 Jun 2026 this includes Lannett.
Europe formulations
Generic medicines sold in European countries. ₹10,315 crore in FY26, 30.7% of revenue; the company said sales passed €1 billion in FY26.
Growth markets
Medicines for other countries, including India. ₹3,499 crore in FY26; India's own branded medicines were ₹302 crore of it.
ARV
Antiretroviral medicines, used to treat HIV. ₹1,384 crore in FY26, 4.1% of revenue.
APIs
Active ingredients sold to other drug makers: ₹2,972 crore of beta-lactam APIs (penicillin-family antibiotics) and ₹1,075 crore of others in FY26.
Biosimilars and contract manufacturing
Copies of biological medicines: 14 in the portfolio in FY26, 4 launched by Q2 FY27. Its unit TheraNym is building plants to make biologics for MSD.
What it does
- Does: Makes generic copies of off-patent medicines for the US and Europe
- Does: Makes active ingredients (APIs) and sells some to other drug makers
- Does: Makes injectable medicines through its subsidiary Eugia Pharma Specialities
- Does: Builds biosimilars and a biologics plant that will make products for MSD
What it does not do
- Does not: Does not earn most of its revenue in India: Indian customers paid 9.9% of FY26 revenue
- Does not: Does not report profit by business: it has one reported segment, pharmaceuticals
- Does not: Does not mainly sell its own patented medicines: ADQUEY, launched in Q2 FY27, is its first new chemical entity
13How the money flows
13How the money flows · FY26
How does money flow through Aurobindo Pharma?
Money in
- Revenue from operations₹33,653 cr
- Other income₹492 cr
The company
Aurobindo Pharma
₹34,145 cr came in
Money out
- Materials and goods bought₹13,488 cr
- Employees₹5,190 cr
- Other running costs₹8,129 cr
- Depreciation and amortisation₹1,778 cr
- Interest₹384 cr
- One-off charge₹65 cr
- Tax, less small joint-venture and minority items₹1,606 cr
- Profit to Aurobindo shareholders₹3,505 cr
- In FY26 Aurobindo took in ₹33,653 crore from sales plus ₹492 crore of other income.
- Materials and goods bought for resale cost ₹13,488 crore, the largest cost.
- Staff cost ₹5,190 crore and other running costs ₹8,129 crore.
- Depreciation took ₹1,778 crore, interest ₹384 crore and tax ₹1,609 crore.
- ₹3,505 crore was left for Aurobindo's shareholders.
Sources (1)
14What it needs to run
14What it needs to run
What does Aurobindo Pharma need to run?
Plants
28 plants in India and 5 abroad; 31 of the 33 were in commercial operation, per the FY26 sustainability report. Plants that supply the US must pass US FDA inspections.
US product approvals
Each US generic needs an approved application (ANDA). By 30 Sep 2026 Aurobindo had filed 900 and won 747 final approvals.
Research
R&D spending was ₹1,590 crore in FY26, 4.7% of revenue (Cityfort calculation).
People
More than 27,000 permanent employees and 13,000 contract workers on 31 Mar 2026.
15Where it sells
15Where it sells · FY26
Where does Aurobindo Pharma sell?
- United States42.7%
- Europe31.8%
- Rest of the world15.7%
- India9.9%
Sources (1)
16Where growth could come from
16Where growth could come from
Where could Aurobindo Pharma's growth come from?
Management said on the Q2 FY27 call (5 Nov 2026) that it reiterated its FY27 guidance: double-digit revenue growth, an EBITDA margin above 21% and EBITDA above ₹8,000 crore, on the company's own measure. It said it aims to expand the margin to "upwards of 22%" in the coming years.
Europe
Working+27.5% in ₹, Q2 FY27
Europe formulation sales rose from ₹2,480 crore in Q2 FY26 to ₹3,161 crore in Q2 FY27 (Cityfort calculation). In euros the rise was 18%, the company said.
Status: Working, on track against what the company said.
US, with Lannett
New+25.2% in ₹, Q2 FY27
US formulation sales were ₹4,555 crore in Q2 FY27, against ₹3,638 crore a year earlier. Lannett is included from 29 Jun 2026, and its sales are not shown separately.
Status: New, recently announced.
Growth markets
Working+16.3%, Q2 FY27
Sales in growth markets, including India, were ₹1,026 crore in Q2 FY27, up from ₹882 crore (Cityfort calculation).
Status: Working, on track against what the company said.
New US products
New10 US launches, Q2 FY27
In Q2 FY27 Aurobindo launched generic Advair and ADQUEY for atopic dermatitis, its first new chemical entity.
Status: New, recently announced.
Biologics for MSD
EarlyUnit 1 qualification planned for Mar 2027 (company)
TheraNym plans 120 KL of capacity for MSD. The company said in its Q2 FY27 presentation (4 Nov 2026) that it expects Unit 1 to be qualified by Mar 2027 and Unit 2, costing about US$180 million, to be ready for qualification in 2030.
Status: Early, too early to judge.
Biosimilars
Early4 launched, 3 filed
The Q2 FY27 deck lists 4 biosimilars launched, 3 filed and 5 advancing.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
17Financial strength and debt
17Financial strength · 31 Mar 2026
How much debt does Aurobindo Pharma have?
- Total debt₹7,676 cr
- Cash and investments₹10,618 cr
- Net cash (cash minus debt)₹2,941 cr
- Net worth (shareholders' money)₹37,891 cr
- Debt to equity
- 0.2×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings exclude lease liabilities (rent owed under leases) of ₹397 crore.
- Cash and liquid investments = cash ₹7,191 crore + other bank balances ₹2,679 crore + current investments ₹747 crore. Net debt is a Cityfort calculation.
- The company's own measure, which also counts non-current investments, showed net cash of ₹1,812 crore (US$189 million) on 30 Sep 2026, with gross debt of ₹8,232 crore.
- Net worth is the equity belonging to Aurobindo shareholders on 31 Mar 2026, before the 2026 buyback.
18Who owns it
18Who owns it · Q2 FY27
Who owns Aurobindo Pharma?
- Promoters (founders or parent company)51.9%, of which pledged 6.2%
- Foreign institutions (FII)17.4%
- Indian institutions (DII)24.4%
- Public and others6.3%
- Pledged: 12.0% of promoter shares (6.2% of all shares)6.2%
Promoter shares pledged
12.0% of promoter shares
A pledge means promoters gave shares as security for a loan. If the loan isn't repaid, the lender can sell them.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (11)
- Shareholding pattern as of 30 Sep 2026 (Reg. 31)
- Shareholding pattern as of 30 Jun 2026 (Reg. 31)
- Shareholding pattern as of 31 Mar 2026 (Reg. 31)
- Shareholding pattern as of 31 Dec 2025 (Reg. 31)
- Shareholding pattern as of 30 Sep 2025 (Reg. 31)
- Shareholding pattern as of 30 Jun 2025 (Reg. 31)
- Shareholding pattern as of 31 Mar 2025 (Reg. 31)
- Shareholding pattern as of 31 Dec 2024 (Reg. 31)
- Shareholding pattern as of 30 Sep 2024 (Reg. 31)
- Shareholding pattern as of 30 Jun 2024 (Reg. 31)
- Shareholding pattern as of 31 Mar 2024 (Reg. 31)
19What it does with profit
19What it does with profit
What does Aurobindo Pharma do with its profit?
Dividend per share
₹4.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Buyback · 19 Aug 2024
Bought back 5,136,986 shares at ₹1,460 each (₹750 crore) by tender offer, approved on 18 Jul 2024 and completed on 19 Aug 2024. The cash flow shows ₹930 crore paid including tax and costs.
₹750 cr
Buyback · 6 Apr 2026
The board approved a buyback of up to 5,423,728 shares at ₹1,475 (up to ₹800 crore) on 6 Apr 2026. Shares outstanding fell to 575,377,895 by 30 Jun 2026.
₹800 cr
20Governance signals
20Governance signals
What do Aurobindo Pharma's governance filings show?
- Auditor
- Deloitte Haskins & Sells
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- Related-party amounts were not extracted for this page. The largest promoter-group holder on 30 Sep 2026 was RPR Sons Advisors Pvt Ltd, jointly with P. Suneela Rani, with 33.54% of the shares.
- Credit rating
- India Ratings IND AA+ (long term), IND A1+ (short term) (outlook Stable), 11 Mar 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
pledge · 30 Sep 2026
Promoter shares pledged
On 30 Sep 2026 promoters had pledged 35,789,000 shares, 11.99% of their holding and 6.22% of all shares. The pledge was 23.65% of their holding on 31 Mar 2026.
regulatory · 14 Aug 2026
US FDA warning letter for Eugia Unit-I
Unit-I of subsidiary Eugia Pharma Specialities is a formulations plant. The company disclosed on 24 May 2026 that the unit had received OAI status; it then received a warning letter on 14 Aug 2026. The company said existing US supplies are not affected and the unit gives about 2% of group revenue.
regulatory · 11 Nov 2026
OAI at Eugia Unit-III and Lannett Seymour
Eugia Unit-III's Jan–Feb 2026 inspection (11 observations) was classified OAI on 12 Jun 2026. Lannett's Seymour, Indiana inspection (4 observations) was classified OAI on 11 Nov 2026.
other · 6 May 2026
Promoter-group SEBI settlement matter
Four promoter-group members had sought a SEBI settlement over alleged insider-trading violations. On 6 May 2026 the Telangana High Court dismissed their petition against SEBI's direction to deposit ₹6.53 crore of trading profits plus 12% interest. The company said the order has no impact on its finances.
disclosure · 4 Nov 2026
One segment; Lannett not shown separately
Aurobindo reports a single segment, so profit by business is not disclosed. Lannett's revenue since 29 Jun 2026 is not split out, so Q2 FY27 growth includes the acquisition.
Sources (10)
- Integrated Annual Report 2025-26 (FY26)
- Shareholding pattern as of 30 Sep 2026 (Reg. 31)
- India Ratings rating letter: bank facilities affirmed IND AA+/Stable/IND A1+
- Shareholding pattern as of 31 Mar 2026 (Reg. 31)
- Eugia Unit-I receives US FDA warning letter
- Eugia Unit-III (Pashamylaram) US FDA inspection classified OAI
- Lannett (Seymour, IN) US FDA inspection classified OAI
- Reg. 30 disclosure: Telangana High Court order on promoter-group SEBI settlement matter
- Unaudited financial results, Q2 FY27 (quarter ended 30 Sep 2026)
- Press release, Q2 FY27 results
21What the market paid
21What the market paid · price as of 13 Nov 2026
What did the market pay for Aurobindo Pharma on 13 Nov 2026?
Price as of 13 Nov 2026 (shown for education; prices change daily).
Price as of 13 Nov 2026: ₹1,823.20, the NSE closing price. Market value = price × 575,377,895 shares (30 Sep 2026) = ₹104,903 crore. P/E shows how many rupees the market price is for each rupee of yearly profit per share: price ÷ ₹68.96 (reported earnings per share for Q3 FY26 to Q2 FY27, added up) = 26.4. Both are Cityfort calculations.
- Share price
- ₹1,823.20
- Market value (market cap)
- ₹104,903 cr
- P/E
- 26.4×
Source: NSE CM bhavcopy, 13 Nov 2026 (AUROPHARMA EQ close); Shareholding pattern as of 30 Sep 2026 (Reg. 31); Earnings presentation, Q2 FY27 and 2 more
22How it got here
22How it got here
How did Aurobindo Pharma get here?
1986
Milestone
Founded in Hyderabad
Incorporated in 1986; started operations with a single manufacturing unit in 1988.
2014
Business-model change
Into Europe with Actavis
Acquired commercial operations from Actavis in Europe, per the timeline in the FY26 annual report.
2019
Business-model change
Apotex Europe and Spectrum products
Acquired Apotex's businesses in five European countries and seven branded cancer injectables from Spectrum Pharma.
2022
Business-model change
Into India's branded market
Entered India's domestic medicine market by acquiring Veritaz Healthcare.
2024
Milestone
Share buyback
Bought back 5,136,986 shares at ₹1,460 each, completed on 19 Aug 2024.
2025
Business-model change
Lannett deal signed
Agreed on 30 Jul 2025 to buy US generics maker Lannett at an enterprise value of US$250 million.
2026
Milestone
Lannett completed; India business moved
Lannett joined on 29 Jun 2026. On 1 Jul 2026 India's branded medicines moved to subsidiary Auropharm Ltd.
2026
Crisis
US FDA actions at three plants
Warning letter for Eugia Unit-I (14 Aug 2026); OAI for Eugia Unit-III (12 Jun) and Lannett Seymour (11 Nov).
Sources (7)
- Integrated Annual Report 2025-26 (FY26)
- Reg. 30 disclosure: agreement to acquire Lannett Company (EV US$250 million)
- Completion of Lannett acquisition (effective 29 Jun 2026)
- Completion of transfer of domestic branded generics business to Auropharm Ltd (w.e.f. 1 Jul 2026)
- Eugia Unit-I receives US FDA warning letter
- Eugia Unit-III (Pashamylaram) US FDA inspection classified OAI
- Lannett (Seymour, IN) US FDA inspection classified OAI
23Sources and changes
Where every number on this page comes from
Sources (42 documents)
- S1Integrated Annual Report 2025-26 (FY26) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 6 Aug 2026
- S2Annual Report 2024-25 (FY25) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 8 Aug 2025
- S3Annual Report 2023-24 (FY24) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 25 May 2024
- S4Annual Report 2022-23 (FY23) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 27 May 2023
- S6Unaudited financial results, Q2 FY27 (quarter ended 30 Sep 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S7Press release, Q2 FY27 results · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S8Earnings presentation, Q2 FY27 · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S9Q2 FY27 earnings call transcript (call of 5 Nov 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 11 Nov 2026
- S11Earnings presentation, Q1 FY27 · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 5 Aug 2026
- S12Q1 FY27 earnings call transcript (call of 6 Aug 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 13 Aug 2026
- S13Press release, Q4 FY26 and FY26 results · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 21 May 2026
- S14Earnings presentation, Q4 FY26 · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 21 May 2026
- S15Q4 FY26 earnings call transcript (call of 22 May 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 22 May 2026
- S17Earnings presentation, Q3 FY26 · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 9 Feb 2026
- S18Q3 FY26 earnings call transcript (call of 10 Feb 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 10 Feb 2026
- S19Press release, Q4 FY24 and FY24 results · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 25 May 2024
- S20Shareholding pattern as of 31 Mar 2024 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Mar 2024
- S21Shareholding pattern as of 30 Jun 2024 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2024
- S22Shareholding pattern as of 30 Sep 2024 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Sep 2024
- S23Shareholding pattern as of 31 Dec 2024 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Dec 2024
- S24Shareholding pattern as of 31 Mar 2025 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Mar 2025
- S25Shareholding pattern as of 30 Jun 2025 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2025
- S26Shareholding pattern as of 30 Sep 2025 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Sep 2025
- S27Shareholding pattern as of 31 Dec 2025 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Dec 2025
- S28Shareholding pattern as of 31 Mar 2026 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Mar 2026
- S29Shareholding pattern as of 30 Jun 2026 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2026
- S30Shareholding pattern as of 30 Sep 2026 (Reg. 31) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 15 Oct 2026
- S31India Ratings rating letter: bank facilities affirmed IND AA+/Stable/IND A1+ · India Ratings and Research (letter hosted on company IR site) · Tier 2: rating agency or regulator · 11 Mar 2025
- S32NSE CM bhavcopy, 13 Nov 2026 (AUROPHARMA EQ close) · National Stock Exchange of India · Tier 1: company or exchange filing · 13 Nov 2026
- S33Reg. 30 disclosure: agreement to acquire Lannett Company (EV US$250 million) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jul 2025
- S34Reg. 30 disclosure: business transfer of Khandelwal Laboratories non-oncology formulations business · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 1 Jan 2026
- S35Outcome of board meeting: buyback of up to 54,23,728 shares at INR 1,475 · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 6 Apr 2026
- S36TheraNym Biologics: additional product schedule with MSD · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 15 Apr 2026
- S37Reg. 30 disclosure: Telangana High Court order on promoter-group SEBI settlement matter · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 16 May 2026
- S38Eugia Unit-III (Pashamylaram) US FDA inspection classified OAI · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 12 Jun 2026
- S39Completion of Lannett acquisition (effective 29 Jun 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 30 Jun 2026
- S40Completion of transfer of domestic branded generics business to Auropharm Ltd (w.e.f. 1 Jul 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 2 Jul 2026
- S41Reg. 30 disclosure: Apitoria to acquire 80% of A1 Biochem contract research business (EV US$17 million) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 23 Jul 2026
- S42Eugia Unit-I receives US FDA warning letter · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 14 Aug 2026
- S43Completion of A1 Biochem acquisition · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 2 Oct 2026
- S44Interim dividend of INR 7 per share for FY27 (record date 11 Nov 2026) · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
- S45Lannett (Seymour, IN) US FDA inspection classified OAI · Aurobindo Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 11 Nov 2026
Changes to this page (v1 · 16 Nov 2026)
- v1 · 16 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.